Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction and other diseases or symptoms

1. A solid oral dosage form comprising about 250 mg to about 500 mg of a therapeutic composition for treating or alleviating lower urinary tract symptoms (LUTS), wherein the therapeutic composition comprises dried cranberry powder and is enriched in cranberry seeds or cranberry seed meal,

wherein the cranberry seeds or cranberry seed meal are present in the therapeutic composition in an amount of about 15% to about 25% by weight of the dried cranberry powder,

wherein the therapeutic composition comprises about 5% to 12% or organic acids by weight,

wherein the therapeutic composition of 250 to 500 mg provides an amount of organic acids of less than about 12.5 to 60 mg, an amount of anthocyanins of less than about 0.175 mg to 0.75 mg, an amount of proanthocyanidins of less than about 0.5 mg to 7.5 mg, and an amount of total phenolics of less than about 4.25 mg to 16.25 mg, and

wherein the solid oral dosage form is a tablet, a capsule, a softgel, a powder, or a granule.

2. The solid oral dosage of claim 1 , wherein the cranberry is Vaccinium macrocarpon.

3. The solid dosage form of claim 1 , wherein the cranberry is Vaccinium microcarpon.

4. The solid dosage form of claim 1 , wherein the cranberry is Vaccinium oxycoccus.

5. The solid dosage form of claim 1 , wherein the cranberry seeds or cranberry seed meal are present in the composition in an amount of about 20% by weight of the dried cranberry powder.

6. The solid dosage of claim 1 , wherein the composition comprises less than 10% of organic acids by weight.

7. The solid dosage form of claim 1 , wherein the composition comprises less than about 15% of sugars by weight.

8. The solid dosage form of claim 1 , wherein the composition comprises from about 1% to about 5% of quinic acid by weight.

9. The solid dosage form of claim 8 , wherein the composition comprises from about 2.2% to about 3.2% of quinic acid by weight.

10. The solid dosage form of claim 1 , wherein the composition comprises from about 0.4% to about 4% of malic acid by weight.

11. The solid dosage form of claim 10 , wherein the composition comprises from about 0.8% to about 1.8% of malic acid by weight.

12. The solid dosage form of claim 1 , wherein the composition comprises from about 1% to about 5% of citric acid by weight.

13. The solid dosage form of claim 12 , wherein the composition comprises from about 1.8% to about 3.2% of citric acid by weight.

14. The solid dosage form of claim 1 , wherein the composition comprises:

0.5% to 5.0% proanthocyanidins, 0.05% to 1.5% quercetin, 0.001% to 0.1% quercetin-3-glucoside, 0.001% to 0.1% quercetin-3-rhamnoside, 0.001% to 0.1% quercetin-3-xyloside, 0.001% to 0.1% quercetin-3-arabinoside, 0.001% to 0.5% myricetin, 0.001% to 0.1% peonidin-3-galactoside, 0.001% to 0.1% peonidin-3-glucoside, 0.001% to 0.1% peonidin-3-arabinoside, 0.001% to 0.1% cyanidin-3-glucoside, 0.001% to 0.1% cyanidin-3-galactoside, 0.001% to 0.1% cyanidin-3-arabinoside, 0.001% to 0.1% protocatechuic acid 0.001% to 0.1% p-coumaric acid, 0.001% to 0.1% caffeoyl-glucoside, 0.001% to 0.1% coumaroyl-glucoside, 0.001% to 0.1% cafeic acid, 0.001% to 0.1% chlorogenic acid or 0.01 to 1.5% ursolic acid by weight.

15. The solid dosage form of claim 14 , wherein the composition comprises:

1.0% to 1.2% proanthocyanidins, 0.16% to 0.20% quercetin, 0.07% to 0.09% quercetin-3-glucoside, 0.03% to 0.04% quercetin-3-rhamnoside, 0.019% to 0.025% quercetin-3-xyloside, 0.025% to 0.035% quercetin-3-arabinoside, 0.010% to 0.014% myricetin, 0.022% to 0.030% peonidin-3-galactoside, 0.0025% to 0.0035% peonidin-3-glucoside, 0.010% to 0.020% peonidin-3-arabinoside, 0.0005% to 0.0015% cyanidin-3-glucoside, 0.015% to 0.030% cyanidin-3-galactoside, 0.010% to 0.025% cyanidin-3-arabinoside, 0.019% to 0.025% protocatechuic acid, 0.04% to 0.06% p-coumaric acid, 0.015% to 0.025% caffeoyl-glucoside, 0.005% to 0.015% coumaroyl-glucoside, 0.010% to 0.015% cafeic acid or 0.030% to 0.04% chlorogenic acid by weight.

16. The solid dosage form of claim 1 , wherein the composition comprises 1 to 100 μg lariciresinol, 1 to 100 μg secoisolariciresinol or 1 to 100 μg pinoresinol per 100 g of the composition by weight.

17. The solid dosage form of claim 16 , wherein the composition comprises about 51 μg lariciresinol, about 12 μg secoisolariciresinol or about 78 μg pinoresinol per 100 g of the composition by weight.

18. The solid dosage form of claim 1 , comprising about 250 mg of the therapeutic composition.

19. The solid dosage form of claim 1 , comprising about 500 mg of the therapeutic composition.